For more updates follow Grant Thornton Bharat on WhatsApp
India has, for a long time, played a central role in the global pharmaceutical supply chain due to its large scale, its scientific talent, and its ability to manufacture at a low cost. The global life sciences sector is currently going through a period of change, with manufacturers now being judged not just on their capacity and cost but also on quality, resilience, innovation, and regulatory confidence. It is for these reasons that life sciences manufacturing in India is now entering a new stage of development, a stage characterised by digital transformation, advanced therapies, supply chain resilience, and reliable quality systems. Because of its solid manufacturing base, India is in a unique position to move from being merely a large-scale producer to becoming a strategic global partner in the areas of innovation, development, and advanced manufacturing.
India is one of the biggest pharmaceutical manufacturing centres in the world.
The country ranks third in the world in terms of the volume of pharmaceutical production and has considerable potential for expanding its involvement in high-value manufacturing.
Over half of India's pharmaceutical exports are to highly regulated markets, which indicates confidence in the capabilities of pharmaceutical manufacturing in India.
Growth is now extending beyond traditional pharmaceuticals to include biologics, biosimilars, specialty medicines, and advanced therapies.
Contract development and manufacturing (CDMO) arrangements are allowing manufacturers to go beyond simple supply relationships and take on the role of innovation partners.
Technologies associated with digital manufacturing are enhancing productivity, traceability, quality assurance, and operational resilience.
Strong data integrity and Quality by Design (QbD) frameworks are now essential for meeting regulatory requirements and gaining the trust of customers.
Risk-based quality management is helping companies to take proactive steps in managing both quality and operational risks.
Various government initiatives, such as the PLI schemes and those focused on research, are speeding up investments in manufacturing and innovation.
The industry, academia, regulators, and investors need to collaborate if India has to maintain its competitive edge.
India's success in the field of pharmaceutical manufacturing has always been based on low costs, large-scale production, and access to global markets. In the last twenty years, Indian pharmaceutical companies have built up a solid position in both regulated and developing markets, thanks to their extensive manufacturing facilities and scientific knowledge.
However, expectations on a global scale are changing. Healthcare systems and pharmaceutical innovators now want manufacturing partners with:
India's opportunity is to combine its advantage in scale with high-value, innovation-driven manufacturing that meets both existing and new healthcare demands.
Since biologics, biosimilars, cell-based therapies and other advanced methods of treatment are having a major impact on healthcare around the world, the sector of biopharmaceutical manufacturing is now a key area of growth for the industry. India is gradually increasing its capabilities in the areas of bioprocessing, fermentation, cell-culture technologies and the production of biologics to meet the growing global demand for complex treatments.
Such a change demands specialised infrastructure, technical knowledge, and a substantial long-term investment. Those organisations which manage to build up their capabilities in the manufacture of biologics will find themselves in a better position to take part in the high-value parts of the life sciences value chain and at the same time support innovation-driven growth throughout the sector.
The development of CDMO services is opening new possibilities for Indian companies in the life sciences sector to increase their global relevance. Nowadays, pharmaceutical and biotechnology companies are looking more and more for integrated partners who can assist with product development, clinical manufacturing, regulatory compliance, commercial production, and lifecycle management.
By moving from a focus on manufacturing execution to entering development-led partnerships, Indian CDMOs will be able to strengthen their relationships with customers, take part in innovation ecosystems, and generate sustainable value. The shift from that of a supplier to that of a strategic partner is one of the major growth opportunities for the sector.
The development of India's life sciences manufacturing industry will depend on the uptake of digital manufacturing technologies, automation, advanced analytics, artificial intelligence, digital quality systems, electronic batch records, and end-to-end traceability platforms all contributing to improved manufacturing consistency and operational performance.
Digital transformation is also providing real-time visibility throughout both production and supply chains, which in turn supports predictive maintenance, quicker decision-making, and greater resilience in the face of disruptions. Since regulatory requirements are becoming more data-driven, digitally enabled operations will be playing an increasingly important role in boosting customer confidence and global competitiveness.
Organisations that manage to combine digital technologies with well-disciplined operating models will probably attain higher reliability, better quality performance, and greater productivity, thus securing a sustainable competitive advantage in the changing global marketplace.
As the industry moves towards more complex therapies and regulatory oversight becomes stricter, quality is becoming a key factor for success. These three practices are no longer optional. They are now essential foundations for sustainable growth.
Builds quality in from the start of product and process development. It uses scientific knowledge and solid process controls to improve consistency and performance.
Uses systematic methods to identify and eliminate potential problems across the product lifecycle, so organisations can manage quality risks proactively instead of reacting to them.
Keeps production and quality records secure, accurate, traceable and ready for audit.
Taken together, these capabilities form the basis for regulatory confidence, customer trust and long-term competitiveness.
The next phase in the development of life sciences manufacturing in India will be determined not only by higher production volumes but also by the industry's capacity to provide reliable quality, carry out manufacturing based on innovation, maintain robust supply chains, and operate with the use of digital technologies. Since the global healthcare ecosystem is still evolving, India has the chance to reinforce its position as a favoured location for the development, manufacture and delivery of advanced life sciences solutions.
India can surpass its traditional strengths and become a globally trusted manufacturing and innovation partner for the future by investing in biopharmaceutical manufacturing, expanding its CDMO capabilities, adopting digital manufacturing, and incorporating data integrity alongside QbD and risk-based quality management throughout its operations.
Close alignment across policy, capital, talent, academia and industry can support this transition. Recent initiatives point in this direction, and sustained collaboration can help translate that momentum into outcomes.
Consistent process control, robust governance and continuous improvement can support the confidence global partners place in a manufacturing location for complex, high-value products.
India ranks third globally in pharmaceutical volume but eleventh in value. Building on established scale to support higher-value, complex and innovation-linked production is a natural next step.
Production-linked incentives, bulkdrug parks and domestic capacity additions have strengthened selected inputs. Continued progress on cluster development, financing access and strong MSME participation can deepen this resilience further
Automation, data integrity, traceability and analytics-led decision-making can improve manufacturing reliability and help turn operational data into more consistent quality and productivity outcomes.
India can surpass its traditional strengths and become a globally trusted manufacturing and innovation partner for the future by investing in biopharmaceutical manufacturing, expanding its CDMO capabilities, adopting digital manufacturing, and incorporating data integrity alongside QbD and risk-based quality management throughout its operations.
In Q2 2026, pharma and healthcare deal activity reflected a selective investment environment. Strategic acquisitions, portfolio strengthening and capability-led expansion remained key themes across the sector.
The consumer and retail sector witnessed sustained investment interest as businesses strengthened category leadership, expanded portfolios and pursued differentiated growth opportunities.
Pharma and healthcare deal activity in Q1 2026 reflects steady volumes alongside a more measured approach to capital deployment.
